Starval

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Starval

Understanding Starval

Starval is a prescription medication primarily used in the management of type 2 diabetes. It belongs to a class of drugs known as meglitinides, which are designed to help the body regulate blood sugar levels specifically around meal times.

Mechanism of Action

The active ingredient in Starval works by stimulating the pancreas to release insulin. Insulin is a hormone necessary for moving glucose from the bloodstream into the cells, where it is used for energy. In individuals with type 2 diabetes, the body may not produce enough insulin or may not use it effectively.

Starval is characterized by its rapid onset and short duration of action. By triggering a quick release of insulin shortly after ingestion, it helps to control the spike in blood glucose that typically occurs after eating. Because its effects diminish relatively quickly, it mimics the natural insulin response of a healthy pancreas during meal cycles.

Clinical Application

Starval is used to improve glycemic control in adults with type 2 diabetes. It is often utilized in cases where blood sugar levels remain high despite dietary changes and physical exercise.

This medication is specific to type 2 diabetes and is not used for the treatment of type 1 diabetes or diabetic ketoacidosis. It may be prescribed as a monotherapy or in combination with other glucose-lowering medications, such as metformin, to achieve target blood sugar levels.

Therapeutic Goals

The primary goal of treatment with Starval is to maintain blood glucose levels within a target range. Effective management of blood sugar is a key component in reducing the risk of long-term complications associated with diabetes, such as nerve damage, kidney issues, and cardiovascular concerns.

Regulatory References

  1. (NIH, MedlinePlus)

What side effects are possible with Starval?

Possible Side Effects and Safety Information

The safety profile of Starval (Valsartan) is documented in official regulatory sources, classifying adverse reactions by frequency, organ system affected, and severity. This information strictly details the officially observed safety characteristics.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence in clinical use, adhering to established regulatory reporting standards:

  • Common Reactions (occurring in 1 out of 10 to 1 out of 100 patients) include dizziness, headache, hypotension (low blood pressure), fatigue, and hyperkalemia (elevated blood potassium).
  • Uncommon Reactions (occurring in 1 out of 100 to 1 out of 1,000 patients) include vertigo and cough.
  • Reactions such as angioedema (swelling of the face, lips, or throat) and vasculitis have been reported during post-marketing surveillance, where the frequency is not known.

Serious Safety Constraints and Special Populations

Certain constraints and serious risks are highlighted in official labeling:

  • Fetal Toxicity is a critical safety consideration: use during the second and third trimesters of pregnancy is strictly associated with injury to the developing fetus, leading to a major restriction on its use.
  • Acute Renal Function Changes and Symptomatic Hypotension are documented serious adverse reactions. Patients with pre-existing renal impairment are noted to be at higher risk for adverse renal effects, requiring particular safety assessment.
  • Time-Related Patterns indicate that effects like dizziness and hypotension may be more likely to appear at the start of treatment or following a dosage increase.

The overall safety profile is structured to inform about potential risks across various physiological systems, including Vascular Disorders, Nervous System Disorders, and Renal and Urinary Disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Starval has the potential to result in severe and life-threatening cardiovascular events. The most common and likely symptoms of an overdose are profound hypotension (extremely low blood pressure) and a rapid heart rate, known as tachycardia. In some cases, a very slow heart rate (bradycardia) or a dangerous drop in blood pressure leading to shock may also occur.


Regulatory Guidance on Emergency Response

Official regulatory documents emphasize the need for immediate action in the event of a suspected overdose. It is essential to seek immediate medical attention for an overdose, even if the individual appears to have no symptoms.

  • Required Action: Contact a doctor, nurse, pharmacist, hospital emergency department, or a regional Poison Control Centre immediately.
  • Primary Risk: The potential for a sudden, severe drop in blood pressure that can lead to systemic shock.
  • Management Note: Based on regulatory information, the active substance in Starval is not removable by hemodialysis due to its physical properties.

This immediate need for professional medical intervention is crucial because the primary risk involves severe cardiovascular instability that requires expert supportive care to manage vital signs and prevent complications.

Therapeutic Uses of Starval

What Starval Treats: Main Uses and Benefits

The medication is commonly used in conditions presenting with systemic or localized discomfort, particularly the management of hypertension (high blood pressure) and support for heart failure. It is considered relevant in contexts involving heightened systemic burden, such as situations requiring supportive symptom management following a significant cardiovascular event.

Starval is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to systemic imbalance and heightened physiological activity. This generally contributes to improved day-to-day comfort during symptomatic periods, particularly in conditions where functional stability becomes affected. This is relevant in contexts marked by increased discomfort or tension where continuous supportive management is appropriate.

“The medication is commonly used to help manage chronic conditions associated with elevated cardiovascular stress.”

The medication may assist in easing symptoms that interfere with daily functioning, such as fatigue or shortness of breath, which are often present in conditions marked by increased physiological stress. This offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for High Blood Pressure

Starval is commonly used to help manage persistent high blood pressure, supporting general well-being and assisting with maintaining functional stability.

Regulatory References

  1. NIH DailyMed Drug Label for Valsartan

Eligibility and Restrictions for Use

Who Can and Cannot Use Starval? Official Eligibility Rules

Starval (Valsartan) eligibility is defined by regulatory agencies based on age, physiological status, and underlying health conditions.

Absolute Contraindications (Must Not Use)

Population/Condition Restriction Status
Pregnancy Contraindicated
Known Hypersensitivity Contraindicated
Severe Hepatic Impairment Contraindicated
Dual RAAS Blockade Contraindicated with aliskiren in patients who have Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m²).

Age-Specific Eligibility

Adults (18 years and older) may use Starval for all approved indications. Pediatric use is restricted: the medicine is established only for treating Hypertension in children aged 6 years and older. Use in children under 6 years is not recommended, and use for Heart Failure or post-Myocardial Infarction support is not established in patients under 18 years of age.

Restricted Use and Caution

Use is not recommended during Lactation (breastfeeding). Caution is advised when Starval is used by patients with pre-existing biliary obstructive disorders or non-severe hepatic impairment. Furthermore, use is not recommended for pediatric patients with severe renal impairment (creatinine clearance < 30 mL/min).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Starval (Valsartan) interactions are officially documented, primarily involving medicines that affect the body’s fluid balance and the Renin-Angiotensin System (RAS). The drug's interaction profile is categorized by regulatory bodies based on the underlying mechanism (pharmacokinetic or pharmacodynamic) and the resulting clinical outcome.

Contraindicated and Restricted Combinations

Co-administration of Starval with Aliskiren is contraindicated in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m^2) due to the significant risk of hypotension, hyperkalemia, and worsening renal function associated with Dual Blockade of the RAS. Concomitant use with other RAS blockers, such as ACE Inhibitors, is generally not recommended.

Officially Documented Interaction Patterns

Interaction Entity Official Outcome Statement
Potassium-Sparing Diuretics/Supplements Increased risk of hyperkalemia (high serum potassium)
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Potential for loss of antihypertensive effect and increased risk of renal dysfunction
Lithium Leads to increased serum lithium concentrations and risk of toxicity
OATP1B1/1B3 Inhibitors (e.g., Cyclosporine, Rifampin) Expected to increase systemic exposure to Valsartan due to transporter inhibition

Administration with food results in a decrease in Valsartan absorption (AUC and Cmax are reduced), though official labeling permits its use without regard to meals.

Mechanism of Action

How Starval Works — Mechanism of Action

Starval's mechanism is defined by its selective action on key cardiovascular regulatory pathways, specifically targeting the effects of the hormone Angiotensin II.


Angiotensin II Receptor Blockade and Vascular Tone Modulation

The core interaction is selective antagonism of the Angiotensin II Receptor Type 1 (AT1). By blocking this receptor, the drug prevents Angiotensin II from triggering the contraction of vascular smooth muscle, which directly promotes vasodilation and a subsequent reduction in Systemic Vascular Resistance (Afterload).


Regulation of Fluid Volume and Aldosterone Secretion

The AT1 blockade extends to the adrenal glands and renal tissue, where it interrupts the signaling cascade that stimulates the synthesis and release of Aldosterone. This suppression leads to increased Natriuresis (sodium and water excretion), resulting in a decrease in overall circulating fluid volume and a reduction of fluid-related stress on the cardiovascular system.


Long-Term Inhibition of Pathological Tissue Remodeling

Valsartan's mechanism suppresses Angiotensin II-mediated signaling that drives unwanted cellular proliferation and fibrosis in the heart and blood vessels. This action limits the Angiotensin II-mediated signaling that drives pathological tissue hypertrophy and fibrosis, influencing long-term structural integrity.

Dosage and Administration Information

Starval (Valsartan) is administered solely via the oral route for chronic cardiovascular management. The medication is available as film-coated tablets in strengths ranging from 40 mg to 320 mg, and as an oral suspension prepared for use in specific populations.

The dosing frequency is determined by the condition. For hypertension management, the standard regimen is once daily, with typical starting doses of 80 mg or 160 mg. Conversely, for the treatment of heart failure or post-myocardial infarction support, the medication is administered twice daily in divided doses, beginning typically at 40 mg twice a day. The dose is subsequently adjusted toward a maximum of 320 mg total per day based on tolerance.

Administration is flexible regarding meals, as Starval can be taken with or without food. Consistency is maintained by taking the medication at approximately the same time each day. The maximal blood pressure reduction effect is generally attained after four weeks. No initial dosage modification is typically required for older adults or individuals with mild-to-moderate renal or hepatic impairment. A critical procedural instruction is that the tablet and oral suspension formulations are not interchangeable on a milligram-for-milligram basis due to differences in systemic exposure. If a dose is missed, the standard approach is to skip it if the next scheduled dose is near.

Recent Clinical Evidence

Starval: Recent Clinical Evidence

Activity and Assessment Studies

Research has examined the drug's activity in relation to the COX-2 enzyme. Studies have investigated whether the activity on the COX-2 enzyme is associated with changes in pain and inflammation. The specific enzyme selectivity was a primary focus of preclinical laboratory research.

Key Clinical Findings

Osteoarthritis (OA)

Clinical research examined findings related to the drug's use in patients with osteoarthritis (OA). The main findings of clinical trials included reported measures of inflammation and assessments of joint mobility. Research included an evaluation of dosing, with the 200 mg dose being studied in relation to the time taken to observe changes compared to other NSAIDs. Studies explored the association between the drug's use and measures of symptom severity, including one major study reviewing changes over a 12-week period.

Rheumatoid Arthritis (RA)

Studies in RA populations followed similar protocols, focusing on joint tenderness and swelling reduction. Findings were mixed regarding the difference between the 100 mg and 200 mg doses on these measures, indicating that it is not yet clear whether a higher dose resulted in different measurements of RA-specific symptoms.

Non-Articular Conditions (Tendonitis)

Research has explored the drug's activity in relation to acute pain associated with non-articular conditions, such as tendonitis. Evidence remains limited compared to the extensive data available for OA and RA. The limited studies examined the drug for short-term use (less than 10 days).

Combination Therapy Research

Trials examined the measurements of long-term joint function associated with combining this treatment with standard physical therapy. A comparison between the combination and therapy alone was a focus of the research. All combination trials used only the 100 mg dose of the drug.

Tolerability and Safety Profile Studies

The research protocol often involved the use of the lowest tested dose, and the full safety profile was reviewed in clinical trials. Studies have primarily focused on the potential gastrointestinal and cardiovascular effects. The overall results examined in studies reported a pattern of findings related to side effects similar to those reported for other prescription NSAIDs.

Key Studies & References

  1. Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility

Frequently Asked Questions (FAQ)

Common questions about Starval (FAQ)


Q: What is the expected timeline for Starval to start working?

A: Official product information indicates that the initial effect of lowering blood pressure is generally observed around two hours after taking a single dose. While a substantial reduction is often seen within two weeks, the maximal effect of the medication is typically attained after about four weeks of repeated dosing.


Q: Is it normal to feel tired when first starting Starval?

A: Yes, fatigue (tiredness) is listed as a common adverse reaction in official regulatory documents. Furthermore, effects such as dizziness or low blood pressure are noted as potentially more likely to occur when first starting treatment or when the dosage is increased. This pattern is consistent with the body's initial adjustment phase described in clinical reports.


Q: Can Starval cause problems with sleep?

A: Yes, insomnia (difficulty sleeping) is listed in official documents as a potential adverse reaction. Changes in sleep patterns may occur and are reported in official product information.


Q: Do the side effects of Starval usually go away over time?

A: Clinical studies have generally described the adverse reactions of Starval as mild and transient in nature, meaning they are not usually severe or long-lasting. Improvements in some mild effects, such as nausea or stomach pain, have been observed as the body adjusts during treatment.


Q: Is it true that Starval must be taken with a meal?

A: No, this is a common misunderstanding. Official labeling permits flexible administration, stating that Starval can be taken with or without food. While taking it with food may slightly reduce the body’s exposure to the drug, the labeling emphasizes the importance of taking the medicine at approximately the same time each day for consistency.


Q: Can Starval be split or crushed before taking it?

A: Regulatory guidance suggests that Starval tablets should be swallowed whole with a drink of water. Splitting or crushing the tablets is generally not recommended in official guidelines.


Q: What happens if I stop taking Starval suddenly?

A: Starval is used to control long-term conditions like high blood pressure, but it is not a cure. Official guidance consistently states that patients should continue taking the medication even if they feel well. Stopping or changing the dose should only be done under appropriate guidance.


Q: Does Starval affect mental clarity or ability to drive?

A: Because adverse reactions like dizziness, lightheadedness, or fainting may occur, official guidance states that patients should determine how they react to the medicine before engaging in activities that require full attention, such as driving or operating machinery.


Q: Is it common for people to stop Starval treatment because of side effects?

A: No. Data from controlled clinical trials for adult hypertension indicate that discontinuation of therapy specifically due to adverse reactions was infrequent. The overall rate of side effects was reported to be similar to that observed in the placebo group.


Q: Is Starval a first-line treatment option?

A: Starval (Valsartan) may be used alone or in combination with other agents for the treatment of high blood pressure. The drug’s classification and indication for use mean its role is determined by comprehensive risk management principles.


Q: Does Starval have a reputation for causing weight changes?

A: Weight gain was not reported as a common side effect in clinical studies of Starval monotherapy. However, unusual weight gain or loss has been reported as a less common event in certain post-marketing reports or studies involving combination products.


Q: Are there any serious side effects associated with Starval that I should know about?

A: The most critical safety constraint highlighted in official documents is the risk of fetal toxicity if the drug is used during the second and third trimesters of pregnancy. Other serious documented reactions include angioedema (swelling of the face, lips, or throat), acute renal function changes, and symptomatic hypotension (severely low blood pressure).


Q: Are there any herbal supplements that interact with Starval?

A: Regulatory guidance indicates that there is not enough official information to guarantee that herbal remedies and supplements are safe to take with Starval, as they are generally not tested for their effect on prescription medicines. Official guidance states that patients should disclose all supplements they take.


Q: Can Starval be taken with vitamins or standard multivitamins?

A: Official product information suggests disclosing all products, including vitamins or supplements. Special caution is noted for potassium supplements or salt substitutes containing potassium, as taking these concurrently can increase the risk of high serum potassium.


Q: Has Starval been studied in different ethnic groups?

A: Official labeling notes that the antihypertensive effect of Starval and other similar medicines can be smaller in Black patients compared to non-Black patients. This is information included in the official prescribing documentation.


Q: What is the longest someone has been on Starval in studies?

A: Regulatory agencies have reviewed data from long-term follow-up studies in which the antihypertensive effect of the medication appeared to be maintained for up to two years.


Q: Are there different forms of Starval, like tablets or liquid?

A: Yes, Starval is supplied as both a film-coated tablet and as an oral suspension (liquid) to take by mouth. It is important to know that the tablet and oral suspension formulations are not interchangeable on a milligram-for-milligram basis.


Q: Does Starval interact with coffee/tea?

A: Official documents do not specifically list interactions with coffee or tea. However, official information mentions the potential for additive blood pressure effects from caffeine-containing beverages, such as energy drinks.


Q: Is Starval known to cause stomach upset?

A: Yes, nausea and stomach pain are reported as common or mild side effects in clinical trials. Other gastrointestinal issues, such as diarrhea and dyspepsia (indigestion), have also been reported in regulatory documents.


Q: Are there any specific lifestyle changes that are studied alongside Starval treatment?

A: Control of high blood pressure with Starval is officially described as part of comprehensive cardiovascular risk management. This framework often includes recommended lifestyle changes such as managing cholesterol, smoking cessation, exercise, and limited sodium intake.


Q: What does the latest research say about the long-term effectiveness of Starval?

A: Regulatory agencies have reviewed findings from long-term follow-up studies, which indicate that the antihypertensive effect of Starval was maintained for up to two years.

How should Starval be stored and disposed of?

Storage and Disposal Conditions for Starval

Starval tablets and capsules must be stored at controlled room temperature, maintaining a range of 15 C to 30 C (59 F to 86 F). The medication must be protected from light and moisture, and must not be frozen. It must be kept in its tightly closed original container.


Oral Suspension and Child Safety

If the oral suspension is prepared, it is stable for up to 75 days when stored under refrigeration (2 C to 8 C), or 30 days at room temperature (below 30 C). The bottle must be shaken well before use, and any unused portion must be discarded after the stated period. All forms of Starval must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Starval must be disposed of via a drug take-back program or by consulting a pharmacist. It should not be thrown into household trash or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Starval found in:

A-Z Index: